Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Bill Wexler's Dog Pound -- Ignore unavailable to you. Want to Upgrade?

To: BDR who wrote (757)	4/18/1999 2:11:00 PM
From: Larry Brubaker	Respond to of 10293

Here's a company with no revenue, negative working capital, one employee, and total assets of $17,000 selling for a market cap of more than $12 million. Subject 21137

To: BDR who wrote (757)	4/18/1999 2:35:00 PM
From: Mkilloran	Respond to of 10293

Dale...VVUS sales of MUSE are doing very well in the UK Sweden and Canada vrs Viagra....look at the latest studies of Muse working on Viagra failures, look at the fact that nitro patients can not use Viagra, heart patients on blood presure medications are at more risk than patients on local applied MUSE...look at the latest studies... Muse is a niche product getting over 15% of the market share of the ED patients when sold to the right market niche ...ASTRA/ZENECA ready to rollout sales in all of Europe this qtr Vivus has no sales force in the USA at present and it still holds a small dedicated piece of the market...look for Astra/Zeneca to become the USA sales partner soon...J&J Janssen is the sales partner in Canada, far east China to be approved in the 3rd qtr.. Look for growing eps going forward..and another $6 million in milestones are due soon.. Expect a partner to be named soon to sell Muse in Japan...more milestone payments followed by sales and EPS growing.. Next generation drug Alibra in phase iii FDA trials to be completed in Sept 99.. better product, less side effects, lest costly, smaller insize, one dose strength, does not require refrigeration stores at room temp More new goodies in the pipeline... This is not the Vivus company that you knew in early 1998... Vivus has got it's act together now.... new CFO onboard, expense controls, new board members inplace, etc